[HN Gopher] MDMA-assisted therapy for PTSD: A randomized, placeb...
___________________________________________________________________
MDMA-assisted therapy for PTSD: A randomized, placebo-controlled
phase 3 trial
Author : beefman
Score : 34 points
Date : 2023-09-15 21:42 UTC (1 hours ago)
(HTM) web link (www.nature.com)
(TXT) w3m dump (www.nature.com)
| notamy wrote:
| > There were no deaths or serious TEAEs [treatment emergent
| adverse event]. These data suggest that MDMA-AT reduced PTSD
| symptoms and functional impairment in a diverse population with
| moderate to severe PTSD and was generally well tolerated.
| prashp wrote:
| But also
|
| > Seven participants had a severe treatment emergent adverse
| event (TEAE) (MDMA-AT, n = 5 (9.4%); placebo with therapy, n =
| 2 (3.9%)).
| [deleted]
| RadixDLT wrote:
| dupe: https://news.ycombinator.com/item?id=37524353
| dang wrote:
| Thanks! but on HN, we don't count reposts as dupes if the story
| hasn't had significant attention yet. This is to give good
| stories multiple changes at getting attention.
|
| This is in the FAQ (https://news.ycombinator.com/newsfaq.html)
| and there are past explanations at
| https://hn.algolia.com/?dateRange=all&page=0&prefix=true&que...
| if interested.
| mountainriver wrote:
| Overall seems positive, some interesting pieces:
|
| > The only measured exploratory covariate with a significant
| interaction with treatment was lifetime history of SSRI use,
| which was associated with improved efficacy of MDMA-AT (P = 0.02;
| Supplementary Table 5). Covariates significantly impacting the
| main effect were sex assigned at birth and baseline Beck
| Depression Inventory (BDI)-II score; female sex assigned at birth
| and baseline BDI-II score >=23 were both associated with improved
| outcomes irrespective of treatment assignment (P < 0.05).
|
| This is an interesting outcome, particularly the SSRI usage
|
| > Eight participants (MDMA-AT, n = 7; placebo with therapy, n =
| 1) experienced cardiac TEAEs, which included palpitations (MDMA-
| AT, n = 5 (9.4%); placebo with therapy, n = 1 (2.0%)) and
| tachycardia (MDMA-AT, n = 2 (3.8%)); all were mild.
|
| Seems a bit concerning, but I have little to measure this
| against.
|
| > superiority of MDMA-AT over SSRIs cannot be assumed without a
| direct comparison
|
| I feel as though this should be done. Even though the results are
| promising they come with a significant safety risk for the
| participants who are essentially at the mercy of the
| administrator and could be easily subject to abuse.
|
| That being said, for people with severe PTSD this is surely a
| godsend. Maybe we can mitigate the safety issue other ways.
| singingfish wrote:
| I've been hearing about this for a long time - probably since the
| late 1990s, so I'm surprised to see that it seems only in the
| last couple of years that there are phase three trials. I would
| imagine that the safety profile of MDMA is already well
| understood / fairly well researched in the 1950s and 1960s
___________________________________________________________________
(page generated 2023-09-15 23:00 UTC)